Corcept Therapeutics Announces Third Quarter Financial Results And Provides Corporate UpdateGlobeNewsWire • 11/03/21
Corcept Therapeutics (CORT) Earnings Expected to Grow: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/26/21
Corcept Therapeutics' Relacorilant Combo Therapy Shows Clinical Benefit In Ovarian CancerBenzinga • 09/17/21
Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian CancerGlobeNewsWire • 09/17/21
Corcept Announces Presentation of Positive Results From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients With Recurrent Platinum-Resistant Ovarian Cancer at ESMO 2021GlobeNewsWire • 09/09/21
Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/30/21
Corcept Therapeutics To Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference CallGlobeNewsWire • 07/22/21
Former Gilead Sciences Executive Amy E. Flood Joins Corcept Therapeutics as Chief Human Resources and Communications OfficerGlobeNewsWire • 07/12/21
Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic CancerBenzinga • 06/22/21
Preliminary Results From RELIANT Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic CancerGlobeNewsWire • 06/22/21
Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/07/21
Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial ResultsGlobeNewsWire • 05/06/21
Addition of Relacorilant to Nab-Paclitaxel Improves Progression Free Survival (PFS) in Controlled, Phase 2 trial of 178 Patients with Platinum Resistant Ovarian CancerGlobeNewsWire • 05/06/21
Corcept Therapeutics (CORT) Sees Hammer Chart Pattern: Time to Buy?Zacks Investment Research • 05/05/21
Earnings Preview: Corcept Therapeutics (CORT) Q1 Earnings Expected to DeclineZacks Investment Research • 04/26/21